Massage Guns Are a Fitness Staple—but Do They Actually Deliver?
From high-tech massage tools to compression boots that look like they belong in a sci-fi movie, the recovery market is overflowing with gadgets that promise to beat soreness and speed up your bounce-back. But just because your favorite gym bro swears by it doesn't mean it actually works—or is worth your hard-earned cash. Case in point: massage guns. A new study suggests they might be more hype than help.
The study published in The Journal of Strength and Conditioning Research followed 20 healthy, active adults as they did an intense biceps workout with their non-dominant arm designed to create soreness and muscle damage.The participants were then broken up into two groups: the group that used a massage gun and the group that didn't do any kind of recovery treatment. The massage gun group used the recovery tool for five minutes right after the workout, then again at 24 and 48 hours later.
For the next week, the researchers tracked how sore each participant's arms felt, how much their range of motion changed, how swollen their muscles were, how strong they stayed, and how well their muscles fired.
The results? Everyone got sore, and everyone recovered to the same extent, whether they used the massage gun or not. That means the massage guns didn't reduce soreness, improve strength, or speed up recovery any more than doing nothing at all.
This study challenges the widely held belief that massage guns are an effective tool for muscle recovery and soreness relief. While they might feel good in the moment (which is a perfectly valid reason to use them), the findings suggest they don't actually help you bounce back any faster after a tough workout.
Massage Guns Are a Fitness Staple—but Do They Actually Deliver? first appeared on Men's Journal on Jul 7, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
How your personality type dictates your exercise routine
A new study suggests an individual's personality type could influence their preferred type of exercise. Researchers believe this link could help those struggling to make lasting changes find something they enjoy. The study involved experts from University College London (UCL) giving 132 volunteers either an eight-week cycling and strength training plan or telling them to rest. Prior to the research, strength levels were evaluated using exercises like press-ups and cycling tests, with stress levels measured on a one to 10 scale. Researchers used the Big 5 personality test to assess dominant personality traits using five distinct groups. These are extroversion, or how energetic and outgoing a person is, agreeableness, which includes attributes related to trust and compassion, conscientiousness, which reflects traits like orderliness and and reliability. The other two traits are neuroticism, which measures emotional stability and the tendency for anxiety or mood swings, and openness, which describes a person's willingness to try new experiences. Dr Flaminia Ronca, of UCL's Surgery and Interventional Science and the Institute of Sport, Exercise and Health (ISEH), said the team found 'some clear links between personality traits and the type of exercise the participants enjoyed most, which I think is important because we could potentially use this knowledge to tailor physical activity recommendations to the individual – and hopefully help them to become and remain more active.' Of the group, some 86 people completed the programme. Researchers found extroverts tended to enjoy high-intensity workouts, such as high intensity interval training (HIIT). Elsewhere, those with strong neuroticism traits preferred bursts of activity over prolonged intensity. They also preferred not being monitored or recording their heart rate during the study, which researchers suggest could indicate they prefer being given space and independence while exercising. 'We know that the global population is becoming increasingly sedentary,' Dr Ronca said. 'You often hear about people trying to become more active, but struggling to make lasting changes. 'In this study, we wanted to understand how personality can influence this to support the development of effective interventions for changes in health behaviour.' Professor Paul Burgess, from the UCL Institute of Cognitive Neuroscience, said, 'people who scored more highly in the neuroticism personality trait showed a particularly strong reduction in stress when they undertook the fitness training recommended in the study. 'This suggests that there may be particular benefits in stress reduction for those with this trait.'
Yahoo
44 minutes ago
- Yahoo
Telix Pharmaceuticals (TLX) Announces That Gozellix® is Commercially Available
Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the The research firm stated that Telix Pharmaceuticals Limited (NASDAQ:TLX) is the most diversified, comprehensively positioned, and standalone publicly-traded radiopharmaceuticals company. The firm also cited the commercial-stage portfolio of targeted radiotherapy agents catering to the unmet needs in oncology. The company announced that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is commercially available nationally in the US. A robotic arm picking up a product assembly line, displaying the company's consumer healthcare and wellness offerings. Telix Pharmaceuticals Limited (NASDAQ:TLX) highlighted that Gozellix builds on proven diagnostic excellence to offer early and accurate detection of metastases at initial staging, with 90% specificity. Telix Pharmaceuticals Limited (NASDAQ:TLX) remains focused on innovation in PSMA imaging, and Gozellix was the result of this commitment. It provides a new level of flexibility in distribution, production, and scheduling, together with a high standard of service and reliability. Notably, PSMA-PET imaging has been established as the standard of care for staging and identifying biochemical recurrence of prostate cancer. That being said, only a relatively small fraction of 3.4 million men having prostate cancer in the US benefited, mainly due to access and availability challenges. Gozellix's enhanced formulation provides a greater level of patient access as well as convenience via an extended transportation distance and clinical administration window. Telix Pharmaceuticals Limited (NASDAQ:TLX)'s stock has a consensus price objective of $22.92. While we acknowledge the potential of TLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
44 minutes ago
- Yahoo
Penumbra (PEN) Announces Completion of Enrollment in STORM-PE Clinical Trial
Penumbra, Inc. (NYSE:PEN) is one of the The company announced the completion of enrollment in STORM-PE clinical trial. The pivotal, prospective, multi-center randomized controlled trial has enrolled 100 patients in order to evaluate computer assisted vacuum thrombectomy (CAVT) through utilising Penumbra's Lightning Flash™ plus anticoagulation, versus anticoagulation alone, for treating acute intermediate-high risk pulmonary embolism (PE). An operating theatre showcasing medical solutions from the company. In the US, an estimated 900,000 cases of symptomatic PE take place annually. Pulmonary embolism could be life-threatening, with 10% – 30% of individuals dying within 1 month of diagnosis. Penumbra, Inc. (NYSE:PEN)'s Lightning Flash portfolio happens to be the most advanced mechanical thrombectomy system on the market, focused on addressing venous and pulmonary thrombus. Penumbra, Inc. (NYSE:PEN)'s gross profit for Q1 2025 came in at $215.9 million, or 66.6% of total revenue, compared to $181.1 million, or 65.0% of total revenue, for Q1 2024. This improvement in gross margin was mainly because of favorable product mix throughout the regions and productivity improvements. Penumbra, Inc. (NYSE:PEN) increased its guidance for the U.S. Thrombectomy franchise growth to 20% – 21% YoY from 19% – 20% previously. It reiterated the guidance for gross margin expansion of a minimum of 100 bps in 2025, to over 67% for FY 2025. Baron Funds, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'We initiated a position in Penumbra, Inc. (NYSE:PEN), a leading manufacturer of medical devices that remove blood clots from veins and arteries. Physicians use the company's devices to treat pulmonary embolism (PE), deep vein thrombosis (DVT), acute limb ischemia, ischemic stroke, coronary disease, and other conditions. Penumbra's devices, which are called mechanical thrombectomy devices, use computer algorithms to modulate the aspiration power depending on if a clot is detected and to control a separate valve that injects saline to reduce friction between the clot and catheter. This enables a differentiated device profile that maximizes clot removal with speed while decreasing risk of blood loss. While we acknowledge the potential of PEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
